NGNE revenueQ4 2025$0
- FY YoY
- -100.0%
NGNE revenue was $0 in fiscal Q4 2025 (ended Dec 31, 2025), compared with $0 a year earlier. For the full fiscal 2025 it was $0, down 100.0% from fiscal 2024.
Neurogene Inc. (NGNE) financials
For fiscal 2025 (ended Dec 31, 2025), Neurogene Inc. reported $0 of revenue and -$90.35M of net income.
- Revenue, FY2025
- $0
- Revenue growth, YoY
- -100.0%
- Net income, FY2025
- -$90.35M
- Free cash flow, FY2025
- -$78.36M
- EPS, diluted, FY2025
- -$4.24
- Cash
- $78.94M
- Market cap
- $505.9M
FY2018FY2025
FY2016FY2025
FY2016FY2025
NGNE revenue and earnings growth
NGNE net incomeQ3 2026-$29.02M
NGNE net income was -$29.02M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$20.95M a year earlier. For the full fiscal 2025 it was -$90.35M, compared with -$75.14M in fiscal 2024.
NGNE EPSQ3 2026-$1.05
NGNE diluted EPS was -$1.05 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.99 a year earlier. For the full fiscal 2025 it was -$4.24, compared with -$4.28 in fiscal 2024.
NGNE free cash flowQ3 2026-$29.46M
NGNE free cash flow was -$29.46M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$19.64M a year earlier. For the full fiscal 2025 it was -$78.36M, compared with -$71.41M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $925.0K | $0 | - | - | - | - | $25.00M | - | - |
| Research and development | $75.01M | $60.92M | $44.39M | $47.51M | $39.16M | $24.34M | $4.42M | $41.79M | $36.27M | $28.38M |
| Selling, general and admin | $28.32M | $22.61M | $11.19M | $9.01M | $21.54M | $17.21M | $18.83M | $15.84M | $14.85M | $9.26M |
| Operating income | -$103.33M | -$82.61M | -$55.58M | -$56.52M | -$60.70M | -$33.73M | -$70.96M | -$32.62M | -$51.12M | -$37.65M |
| Interest expense | $5.0K | $12.0K | $12.0K | $2.0K | - | - | $1.0K | $4.0K | $4.0K | $1.0K |
| Pre-tax income | -$90.35M | -$75.14M | -$36.32M | -$55.19M | -$60.69M | -$33.28M | -$69.44M | -$31.59M | -$50.18M | -$37.00M |
| Income tax | $0 | $0 | - | - | - | - | - | - | - | $0 |
| Net income | -$90.35M | -$75.14M | -$36.32M | -$55.19M | -$60.69M | -$33.28M | -$69.44M | -$31.59M | -$50.18M | -$37.00M |
| EPS, basic | -$4.24 | -$4.28 | - | -$5.20 | -$5.50 | -$3.20 | -$12.85 | -$6.70 | -$10.70 | -$9.80 |
| EPS, diluted | -$4.24 | -$4.28 | - | -$5.20 | -$5.50 | -$3.20 | -$12.85 | -$6.70 | -$10.70 | -$9.80 |
| Diluted shares | 21.3M | 17.6M | - | 11.0M | 11.0M | 10.4M | 5.4M | 4.7M | 4.7M | 3.8M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $103.84M | $136.93M | $148.72M | $82.02M | $70.54M | $193.43M | $143.09M | $76.93M | $52.03M | $32.30M |
| Short-term investments | $165.17M | $175.82M | $48.95M | $0 | $0 | - | - | - | - | - |
| Current assets | $271.77M | $315.92M | $200.35M | $84.72M | $143.99M | $194.52M | $143.60M | $77.17M | $108.83M | $103.48M |
| Total assets | $288.60M | $335.73M | $222.57M | $109.27M | $163.26M | $210.52M | $147.02M | $77.62M | $110.33M | $154.38M |
| Current liabilities | $16.41M | $15.16M | $22.97M | $6.65M | $8.64M | $7.89M | $4.74M | $4.63M | $10.96M | $9.52M |
| Total liabilities | $23.72M | $25.36M | $36.55M | $10.64M | $20.40M | $19.30M | $5.34M | $4.95M | $11.44M | $9.72M |
| Shareholders' equity | $264.89M | $310.38M | $186.02M | -$145.74M | -$91.88M | $191.22M | $141.69M | $72.67M | $98.89M | $144.66M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$77.17M | -$70.60M | -$51.42M | -$52.82M | -$47.56M | -$24.57M | -$15.39M | -$31.58M | -$44.72M | -$30.23M |
| Capital expenditures | $1.18M | $808.0K | $321.0K | $2.23M | $3.26M | $2.22M | $879.0K | $49.0K | $494.0K | $713.0K |
| Free cash flow | -$78.36M | -$71.41M | -$51.74M | -$55.05M | -$50.82M | -$26.79M | -$16.27M | -$31.63M | -$45.21M | -$30.94M |
| Investing cash flow | $14.00M | -$125.26M | $25.64M | -$2.23M | -$3.26M | -$2.22M | -$688.0K | $55.95M | $64.01M | -$48.06M |
| Financing cash flow | $30.43M | $184.07M | $92.48M | $66.53M | $732.0K | $77.14M | $82.24M | $570.0K | $423.0K | $71.11M |
| Stock-based compensation | $14.18M | $8.32M | $1.42M | $1.25M | $11.56M | $5.62M | $7.68M | $4.70M | $3.84M | $1.97M |
| Depreciation and amortization | $3.04M | $3.19M | $3.26M | $3.20M | $1.31M | $785.0K | $340.0K | $289.0K | $360.0K | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -100.0% | - | - | - | - | - | - | - | - | - |
| Operating margin | - | -8930.3% | - | - | - | - | - | -130.5% | - | - |
| Net margin | - | -8123.7% | - | - | - | - | - | -126.3% | - | - |
| Free cash flow margin | - | -7720.1% | - | - | - | - | - | -126.5% | - | - |
| Return on equity | -34.1% | -24.2% | -19.5% | - | - | -17.4% | -49.0% | -43.5% | -50.7% | -25.6% |
| Return on assets | -31.3% | -22.4% | -16.3% | -50.5% | -37.2% | -15.8% | -47.2% | -40.7% | -45.5% | -24.0% |
| Current ratio | 16.56 | 20.84 | 8.72 | 12.74 | 16.67 | 24.66 | 30.28 | 16.68 | 9.93 | 10.87 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | $0 | $0 | $0 | $0 | $0 | $0 | $925.0K | $0 | $0 |
| Research and development | $23.52M | $25.47M | $25.15M | $20.64M | $17.24M | $19.37M | $17.76M | $15.35M | $16.29M | $15.74M | $13.54M | $12.18M |
| Selling, general and admin | $8.85M | $11.20M | $8.20M | $6.89M | $6.56M | $6.71M | $8.16M | $6.17M | $5.89M | $5.32M | $5.24M | $2.55M |
| Operating income | -$32.38M | -$36.67M | -$33.35M | -$27.53M | -$23.80M | -$26.08M | -$25.92M | -$21.51M | -$22.18M | -$20.13M | -$18.78M | -$14.73M |
| Interest expense | $0 | $0 | $0 | $1.0K | $1.0K | $1.0K | $2.0K | $2.0K | $3.0K | $4.0K | $3.0K | $3.0K |
| Net income | -$29.02M | -$34.49M | -$30.93M | -$24.73M | -$20.95M | -$22.02M | -$22.65M | -$19.51M | -$20.22M | -$18.49M | -$16.92M | $2.38M |
| EPS, basic | -$1.05 | -$1.53 | -$1.39 | -$1.12 | -$0.99 | -$1.05 | -$1.08 | -$1.00 | -$1.19 | -$1.09 | -$1.00 | - |
| EPS, diluted | -$1.05 | -$1.53 | -$1.39 | -$1.12 | -$0.99 | -$1.05 | -$1.08 | -$1.00 | -$1.19 | -$1.09 | -$1.00 | - |
| Diluted shares | 27.7M | 22.6M | 22.3M | - | 21.2M | 21.1M | 21.0M | - | 17.0M | 16.9M | 16.9M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $78.94M | $112.48M | $124.16M | $103.84M | $71.34M | $59.15M | $71.11M | $136.93M | $66.97M | $111.37M | $150.48M | $148.72M |
| Short-term investments | $280.78M | $112.91M | $119.02M | $165.17M | $194.41M | $215.71M | $221.83M | $175.82M | $72.36M | $42.87M | $19.39M | $48.95M |
| Current assets | $362.74M | $228.91M | $246.75M | $271.77M | $270.52M | $278.99M | $296.40M | $315.92M | $143.65M | $159.15M | $174.14M | $200.35M |
| Total assets | $377.90M | $244.36M | $263.14M | $288.60M | $287.83M | $297.32M | $315.30M | $335.73M | $164.12M | $179.82M | $195.35M | $222.57M |
| Current liabilities | $18.16M | $21.50M | $18.87M | $16.41M | $14.71M | $15.44M | $14.09M | $15.16M | $15.80M | $13.07M | $11.82M | $22.97M |
| Total liabilities | $23.11M | $27.23M | $25.36M | $23.72M | $22.29M | $24.06M | $23.51M | $25.36M | $26.71M | $24.81M | $24.57M | $36.55M |
| Shareholders' equity | $354.79M | $217.13M | $237.78M | $264.89M | $265.54M | $273.25M | $291.80M | $310.38M | $137.41M | $155.01M | $170.78M | $186.02M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$29.14M | -$23.76M | -$26.12M | -$17.43M | -$19.51M | -$19.46M | -$20.77M | -$17.50M | -$15.56M | -$15.89M | -$21.65M | -$16.97M |
| Capital expenditures | $315.0K | $354.0K | $281.0K | $128.0K | $127.0K | $148.0K | $780.0K | $116.0K | $167.0K | $460.0K | $65.0K | $128.0K |
| Free cash flow | -$29.46M | -$24.11M | -$26.40M | -$17.56M | -$19.64M | -$19.61M | -$21.55M | -$17.61M | -$15.73M | -$16.35M | -$21.71M | -$17.10M |
| Investing cash flow | -$165.99M | $6.10M | $46.24M | $29.61M | $21.99M | $7.45M | -$45.05M | -$102.62M | -$28.97M | -$23.61M | $29.93M | $25.83M |
| Financing cash flow | $161.60M | $5.98M | $195.0K | $20.66M | $9.71M | $54.0K | $4.0K | $190.06M | $131.0K | $399.0K | -$6.52M | $94.30M |
| Stock-based compensation | $5.15M | $7.86M | $3.63M | $3.36M | $3.37M | $3.41M | $4.05M | $2.49M | $2.47M | $2.31M | $1.04M | $355.0K |
| Depreciation and amortization | $821.0K | $813.0K | $847.0K | $776.0K | $800.0K | $800.0K | $749.0K | $785.0K | $800.0K | $800.0K | $814.0K | $817.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | -100.0% | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | -2176.6% | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | -1999.1% | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | -1767.9% | - | - |
| Current ratio | 19.97 | 10.64 | 13.08 | 16.56 | 18.39 | 18.07 | 21.03 | 20.84 | 9.09 | 12.17 | 14.74 | 8.72 |
Source: XBRL data Neurogene Inc. files with the SEC, latest filing dated Nov 9, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-5, first reported Nov 14, 2023.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
NGNE peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NGNE | $0 | -100.0% | -$90.35M | - | $505.9M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
NGNE FAQ
8 questionsWhat is NGNE revenue?
Neurogene Inc. (NGNE) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 100.0% from the year before.Is NGNE profitable?
No. Neurogene Inc. reported a net loss of $90.35M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does NGNE have?
Neurogene Inc. reported $78.94M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is NGNE revenue growing?
Neurogene Inc.'s revenue changed -100.0% in fiscal 2025, to $0.What is NGNE free cash flow?
Neurogene Inc. generated -$78.36M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$77.17M less capital expenditures.What is NGNE earnings per share?
Diluted earnings per share were -$4.24 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did NGNE last report financial results?
The latest statements here come from Neurogene Inc.'s 10-Q filed on Nov 9, 2026, covering the period ended Sep 30, 2026.Where does this NGNE financial data come from?
Quantisnow builds these statements from the structured XBRL data Neurogene Inc. files with the SEC. It is provided for information only and is not investment advice.